Is the CSL share price currently overvalued?

We examine the current analyst outlook on the biotech giant in the wake of its interim results.

In regard to the central question: the current average analyst price target may indeed suggest that CSL has run ahead of its fair value, if only by a little. According to Bloomberg Data, the average 12-month price target on CSL currently sits at $314.06 per share – roughly 5.7% lower than the biotech giant’s current share price.

Moreover, the stock, now with a market capitalisation of $150 billion, has see its share price rise an incredible ~76% in the last 12-months.

Do you own CSL shares? You can hedge your downside risk by trading CFDs now.

This is not to say that analysts don’t favour the stock – or that analysts won’t upgrade their price target on the CSL; after all, they spent much of CY19 doing just that – only that at current price levels, the stock may have run ahead of itself.

Indeed, a more granular breakdown of the analyst view shows that CSL has 8 buy ratings, against 6 hold ratings and just 2 sell ratings.

Moreover, this is also not to suggest that CSL is not an excellently run company. As part of the company’s interim results last week the biotech reported an increased interim dividend, stronger H1 earnings and even upgraded its full-year earnings guidance.

'Our results reflect the focused execution of our strategy, robust demand for our differentiated medicines and a deep, inherent passion for meeting the evolving needs of our patients,’ said the company’s Chief Executive, Paul Perreault.

CSL share price: Macquarie & UBS views

Analysts also remain clued in on the strength of CSL, with Macquarie analysts noting that:

'We continue to see CSL's plasma collection centre network as a competitive advantage relative to peers, supporting our expectations for above-industry Ig growth over the balance of FY20 and FY21.'

Competitive advantages however need be tempered against valuations, with Macquarie pointing out that much of the company’s growth is already factored into the current share price.

In step with that, Macquarie downgraded the biotech to ‘neutral’ from ‘outperform’ last week, and assigned CSL a 12-month price target of $324 per share.

UBS, while far more bullish than Macquarie, pointed out that even when considering the favourable earnings upgrade as part of the company’s H1 results, CSL trades at a significant premium to the market. According to UBS, CSL is now trading at a ~47x FY20e earnings (on a diluted basis).

The ASX 200, by comparison, trades at ~19x FY20 earnings, according to Bloomberg Data.

Nonetheless, UBS has a 12-month price target of $365 per share on CSL.

Practise trading Australian stocks with an IG demo account now.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.


Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.